Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

Yanhang Gao(Jilin University), Jidong Jia(National Clinical Research Center for Digestive Diseases), Yujuan Guan(Guangzhou Eighth People's Hospital), Guicheng Wu(Fujian Medical University), Zhuangbo Mou(Jinan Infectious Disease Hospital), Qing Mao(Army Medical University), Zhansheng Jia(Tang Du Hospital), Jian-Mei Lin(Sichuan Provincial Hospital of Traditional Chinese Medicine), Hai‐Feng Pan(Anhui Medical University), Sujun Zheng(Beijing Tian Tan Hospital), Yanhua Ding, Huichun Xing(Capital Medical University), Desheng Zhou(Technology Holding (United States)), Cheng Li(Dana-Farber Cancer Institute), Li Li(Technology Holding (United States)), Yongfeng Yang(Nanjing Drum Tower Hospital), Guangming Li(The Sixth People's Hospital of Zhengzhou), Qin Ning(Huazhong University of Science and Technology), Chenghao Li(Yanbian University Hospital), Hong Qin(Tumor Hospital of Guangxi Medical University), Fei Kong(Shanghai Jiao Tong University), Xiaofeng Wen(Liuzhou General Hospital), Zhiliang Gao(Sun Yat-sen University), Xiaofeng Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaozhong Wang(Fujian Medical University), Jing Ning(The University of Texas MD Anderson Cancer Center), Jinghua Hu(Chinese PLA General Hospital)
Liver International
August 9, 2020
Cited by 22


Related Papers